Celularity Announces $45 Million Purchase Order, First
Builds on Celularity’s December 2022 announcement of Halal Certification of its commercial-stage biomaterial products, and clinical and investigational...
Source: globenewswire.com
📰 Nasdaq Celu News
Page 2 - Nasdaq Celu News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Celu. Real-time updates on events, politics, business and more.
Celularity Inc. (NASDAQ:CELU) Sees Significant Drop in Short Interest
Celularity Inc. (NASDAQ:CELU – Get Rating) saw a significant drop in short interest in the month of April. As of April 15th, there was short interest totalling 3,790,000 shares, a drop of 26.7% from the March 31st total of 5,170,000 shares. Approximately 5.4% of the company’s shares are sold short. Based on an average daily […]
Source: themarketsdaily.com
Celularity Inc. (NASDAQ:CELU) Short Interest Update
Celularity Inc. (NASDAQ:CELU – Get Rating) was the recipient of a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 5,170,000 shares, an increase of 8.8% from the March 15th total of 4,750,000 shares. Based on an average daily volume of 570,100 shares, the days-to-cover […]
Source: theenterpriseleader.com
Short Interest in Celularity Inc. (NASDAQ:CELU) Expands By 8.8%
Celularity Inc. (NASDAQ:CELU – Get Rating) was the recipient of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 5,170,000 shares, a growth of 8.8% from the March 15th total of 4,750,000 shares. Approximately 7.4% of the company’s shares are short sold. Based on […]
Hb Wealth Management Allspring Global Investments Holdings Morgan Stanley Celularity Inc Renaissance Technologies Celularity Company Profile
Source: modernreaders.com
Short Interest in Celularity Inc. (NASDAQ:CELU) Grows By 38.1%
Celularity Inc. (NASDAQ:CELU – Get Rating) was the target of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 4,750,000 shares, a growth of 38.1% from the February 28th total of 3,440,000 shares. Currently, 9.2% of the company’s shares are sold short. Based on […]
York Mellon Corp Blackrock Inc B Riley Financial Inc Celularity Inc Morgan Stanley Vanguard Group Inc
Source: modernreaders.com
Celularity's Placental-Derived Allogeneic Cell Therapy
Legacy studies employing a single treatment course of two infusions seven days apart demonstrated greatest benefit in three early studies Data support...
Sharmila Koppisetti Carlos Ramirez Robertj Hariri Clinical Affairs Exchange Commission Celularity Inc
Source: globenewswire.com
Celularity Appoints Paul Graves as Chief Communications
Veteran executive brings more than 30 years of biopharmaceutical public relations and public affairs experience...
Hill Knowlton Carlos Ramirez Robertj Hariri Takeda Pharmaceuticals Celularity Inc Chandler Chicco Agency New York
Source: globenewswire.com
Celularity Reports Third Quarter 2022 Financial Results and
Announced first patient treated in Phase 1/2a clinical trial for CYNK-101 in first-line advanced HER2 positive gastric and gastroesophageal junction...
Adrian Kilcoyne Brad Glover Carlos Ramirez Robertj Hariri Johnr Haines Society For Immunotherapy Of Cancer
Source: globenewswire.com
Celularity Presents Preclinical Data on CYNK-101, its
FLORHAM PARK, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing...
United States Carlos Ramirez Exchange Commission Celularity Inc Society For Immunotherapy Of Cancer Boston Convention Exhibition Center
Source: globenewswire.com
Celularity Appoints Adrian Kilcoyne, M.D., M.P.H., M.B.A.,
Veteran pharmaceutical executive brings more than 15 years of proven oncology and immunology experience...
Adrian Kilcoyne Robert Hariri Carlos Ramirez Patient Affairs Drug Administration Head Of Global Medical Affairs
Source: globenewswire.com